Results 71 to 80 of about 4,597 (153)

The Challenges of Living with and Caring for a Child or Children Affected by Neuronal Ceroid Lipofuscinosis Type 2 Disease: In-Depth Family Surveys in the United Kingdom and Germany

open access: yesJournal of Inborn Errors of Metabolism and Screening
Limited research has investigated the challenges faced by families caring for children with neuronal ceroid lipofuscinosis type 2 (CLN2) disease. Face-to-face, mixed-method, in-depth surveys were conducted with 19 families (23 children) in the UK (n=9 ...
Angela Schulz   +10 more
doaj   +1 more source

A Single-Center Review of Infusion-Associated Reactions in Patients with CLN2 Disease Receiving Cerliponase Alfa

open access: yesBiologics
Background: Cerliponase alfa is an intracerebroventricular (ICV) enzyme replacement therapy (ERT) and the only approved treatment for neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
Rebecca Whiteley   +8 more
doaj   +1 more source

Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa

open access: yesFrontiers in Neurology
IntroductionThis study assessed the real-world effectiveness and safety of the enzyme replacement therapy (ERT), cerliponase alfa, to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease.MethodsData from the DEM-CHILD database were analyzed ...
Angela Schulz   +11 more
doaj   +1 more source

Early diagnosis of neuronal ceroid lipofuscinosis type 2 – a myth or reality?

open access: yesPaediatria Croatica, 2020
Neuronska ceroidna lipofuscinoza-tip 2 (CLN2) najčešća je dječja progresivna neurodegenerativna bolest. Glavna obilježja bolesti CLN2 su usporen razvoj govora koji prethodi epileptičkim napadajima, motoričkim poremećajima, progresivnom propadanju vida i kognitivnih funkcija te smrti u dobi rane adolescencije.
openaire   +3 more sources

Peripapillary Retinal Nerve Fiber Layer (pRNFL) Thickness – A Novel Biomarker of Neurodegeneration in Late-Infantile CLN2 Disease

open access: yesEye and Brain
Nikolaos Gkalapis,1,2,* Simon Dulz,1,* Carsten Grohmann,1 Miriam Nickel,3 Christoph Schwering,3 Eva Wibbeler,3 Martin Stephan Spitzer,1 Angela Schulz,3 Yevgeniya Atiskova1 1Department of Ophthalmology, University Medical Center Hamburg-Eppendorf,
Gkalapis N   +8 more
doaj  

Maculopathy and adult‐onset ataxia in patients with biallelic MFSD8 variants

open access: yesMolecular Genetics & Genomic Medicine
Background Biallelic variants in the major facilitator superfamily domain containing 8 gene (MFSD8) are associated with distinct clinical presentations that range from typical late‐infantile neuronal ceroid lipofuscinosis type 7 (CLN7 disease) to ...
Sigurd Dobloug   +6 more
doaj   +1 more source

Classic and Atypical Late Infantile Neuronal Ceroid Lipofuscinosis in Latin America: Clinical and Genetic Aspects, and Treatment Outcome with Cerliponase Alfa

open access: yesMolecular Genetics and Metabolism Reports
Introduction: Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), is a neurodegenerative autosomal recessive disease caused by TPP1 gene variants, with a spectrum of classic and atypical phenotypes.
Norberto Guelbert   +34 more
doaj   +1 more source

Atypical neuronal ceroid lipofuscinosis type 2 disease (CLN2): a case report

open access: yesArquivos de Neuro-Psiquiatria, 2023
Mariana Braga Valadão   +5 more
openaire   +1 more source

Proteomic analysis of blood serum in bipolar disorder

open access: yesEuropean Psychiatry
Introduction Bipolar disorder (BD) often has symptoms similar to other mental disorders (BD), and there are no paraclinical criteria for differential diagnosis. (Geoffroy et al. Bip Dis 2017; 5 7).
L. Smirnova   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy